Академический Документы
Профессиональный Документы
Культура Документы
David P. Humber
School of Biosciences
University of East London
1
Learning Outcomes
2
The Problem
At Risk
• More than 40% of the world population
Deaths
• More than 2 million per year
Chemotherapy
• Limited Drugs & drug resistance
Vector control
Vaccination 3
The Parasite - Taxonomy
4
Species Infecting Humans
Common & Severe
Plasmodium falciparum
• Malignant tertian (Cerebral)
Plasmodium vivax
• Tertian
Plasmodium ovale
• Tertian
Plasmodium malariae
• Quartan Rare & Mild
5
Species Infecting Humans
Relapses Fevers
Plasmodium falciparum No 24-48
6
Epidemiology
>400 million cases annually
3 million deaths
majority 2-5 years
103 endemic countries
most in Africa
most due to P.falicparum
Need 15oCfor 4 weeks <300m
64oN to 32oS
7
Distribution of Malaria
8
Life Cycle
Trophozoite
Oocyst
RBC
Merozoite
Ookinete
Gametocytes 9
Infected Liver CellHepatocyte
Pre-erythrocytic schizonts
10
Erythrocytic forms (signet)
P.falciparum
Macro
Micro
12
Exflagellation
Pre-patent Period
• Time taken from infection to symptoms
– P. falciparum 6-12 days
– P. vivax 10-17days
– P ovale 14 days
– P. malariae 28-30 days
14
Clinical Features of Malaria
17
Falciparum Malaria
18
Fever Charts
19
Untreated P. falciparum malaria
20
Site Specific Sequestration
Brain
• measurable reduction in blood flow
Intestines
• diarrhoea
Placenta
• intervillus space
21
Hepatosplenomegaly
Hepatic dysfunction
Hyperplasia of splenic/liver macrophages
Normally transient
• related to parasite load
Tropical splenomegally
• Proportion of adult develop very large spleens
• Genotype/IR genes
22
Hepato-splenomegaly
Coma 6- 96 hours
• shorter in children
20% fatality
Hepatoslenomegaly common
Retinal haemorrhages
24
Cerebral Malaria
26
Nephrosis
27
Nephrosis
P. Malariae
quarten nephrosis 28
Blackwater Fever
30
Section of Placenta
31
Diagnosis
Clinical symptoms
– Regular fevers / possible exposure
Stained fixed blood smear
– Thick film - presence/absence
– Thin film - morphology/species
Blood
– Capillary - fluorescence
– Antigen capture
– PCR/Mabs
32
Chemotherapy
Quinine
• Extract of tree bark
• used since 17th century
• 1.3 - 2.0g/day for 7 -10 days
• Tonic water!
– Methylene blue
– pamaquine
– mepacrine
33
Synthetic antmalarials
Chloroquine
• Developed by Bayer in 1934 (toxic!)
• Rediscoved in the mid 1940’s
– selective uptake by food vacuole
– intefers with haem polymersiation/detox reactive
oxygen species
• Resistance in humans early 1960’s
34
Other Antimalarials
Proguanil - 1948
Primaquine - 1951
Pyrimethamine - 1952
Cycloquanil - 1963
Monotherapy
Treatment
• high dose short term
Prophylaxis
• low dose long term
36
Immune Mechanisms
Antibody blocks merozoite infection of RBC’s
• passive transfer experiment in the Gambia
Enhance clearance through opsonisation
ADCC likely
NK activity
Decrease in circulating T cells
Down regulation of T cell function
Spleen - spleenectomy!
37
Cytokines
IL1
TNF
IL10
38
Stage specific
40
Immunopathology
Fever
• correlates with schizont rupture
• IL1 & TNF
Anaemia
• common complication exceeds parasitemia &
may worsen after treatment
• T cell control of spllenomegally/bone marrow
41
Immunopathology 2
Cerebral malaria
• highly reversible
• Under T cell control - IL1/TNF
Glomerulonephritis
• Not very common - acute nephritis reversed by
treatment
• IgM, IgG & C3 - autoimmune?
• treatment mediated
42